Gemelli University Hospital

Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG) is the largest private hospital in Italy and a non-profit organization foundation under private law. It was created in 1964 as teaching hospital of the School of Medicine of Università Cattolica del Sacro Cuore (UCSC) and from 2015 it became an independent legal entity from the University. FPG works together with UCSC, sharing medical staff, education/teaching responsibilities and research purposes under a collaborative framework agreement.  In 2018, Fondazione Policlinico Universitario Agostino Gemelli was recognised by the Italian Ministry of Health as IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico – Institute of Research and Care) for “Personalised Medicine” and “Innovative biotechnologies”. From 2021 until now, FPG has been ranked by the Newsweek as the Best Italian Hospital (ranked 38th at international level).  In June 2021, FPG also became Joint Commission International Accredited Healthcare organisation.

FPG has a total of 1581 beds and cares for approximately 95.000 in-patients each year at the hospital.  The hospital staff includes more than 5,000 employees with about 1000 physicians and more than 2,000 nurses. Every day, the hospital hosts an estimated number of 20,000 people.

In terms of research activity, FPG currently manages more than 110 grants by Competitive Calls for a value of €26 mln and more than 200 non-profit studies from private funders for a value of €27mln.

FPG consists of 8 Departments and 150 Operational Units including, the “Gemelli Science and Technology Park” (G-STeP), which is of particular importance, as it is part of a broad program established by the Scientific Direction aimed at enhancing, connecting and structuring all the research activities that take place in the hospital. G-STeP is a network of services in support of all stages of the development of a scientific research project. G-Step comprises of more than 20 Research Core Facilities that offer research services divided by technological themes and “modus operandi”, which are able to provide specific services with certified quality.

These services are made possible via a G-Step App, through which researchers have direct access to the services to optimize and speed up the development of their projects.

For more information about FPG performance can be found in the “Mission Statements” released annually:

Role of institution in the project

FPG is involved in WP2 (Engagement and Liaison of Data Providers), WP6 (Federated Data Processing & Analysis) and WP7 (Use cases & Platform Expansion). The institution will contribute to this project as data providers; by providing data processing/analysis solutions; support in the definition of use cases and platform expansion.

Evis Sala

Evis Sala is a Professor of Radiology and Chair of Department of Radiology at Università Cattolica del Sacro Cuore and Fondazione Policlinico Universitario Agostino Gemelli IRCC, Rome. Italy. Previously, she was the Professor of Oncological Imaging at the University of Cambridge, UK and co-led the Cancer Research UK Cambridge Centre Advanced Cancer Imaging and the Integrated Cancer Medicine Programs. From 2012 to 2018, she served as the Professor of Radiology at Weil Cornell Medical College and Chief of Body Imaging Service at Memorial Sloan Kettering Cancer Center in New York. Her research in the field of radiogenomics integrates quantitative imaging methods for evaluation of spatial and temporal tumour heterogeneity with genomics, proteomics and metabolomics. She is leading multiple research projects focusing on the development and implementation of artificial intelligence methods for image reconstruction, segmentation, and data integration. In recognition for her contribution to education and research in oncological imaging, she received the Radiology Society of North America (RSNA) Honoured Educator Award in 2014, 2017 and 2020 and was elected Fellow of the International Society for Magnetic Resonance in Medicine in 2015 and awarded an Honorary Membership of RSNA in 2022.

Luca Boldrini

Luca Boldrini is a radiation oncologist and the Head of the hybrid MR guided radiotherapy unit at Fondazione Policlinico Gemelli of Rome, Italy. He is also the Head of the Radiomics, Gemelli Science and Technology Park core-research facility (G-STeP). He currently coordinates different research groups primarily focused on the role of hybrid MRI in radiotherapy, radiomics, imaging applications in the frame of personalised medicine and innovative technologies implementation in cancer care. He also holds the position of the scientific coordinator of the Radiomics working group of the italian cancer research network "Alleanza contro il Cancro" that accounts for more than 120 members from 28 primary research institutes all over the country. Besides his main research activity on imaging, he is an advisor for the Clinical research strategy of the “Gemelli Generator” research project, an innovative centre with multidisciplinary skills, which originates from the awareness of the need for tools capable of collecting, storing and analysing huge amount of data generated every day from heterogeneous sources, translating them into understandable and usable information.

Diepriye Charles-Davies

Diepriye Charles-Davies is the Data manager and Clinical Trial study coordinator of the Radiomics, Gemelli Science and Technology Park core-research facility (G-STeP) at Fondazione Policlinico Gemelli. He has an academic background in Biotechnology and experience in executing both laboratory and clinical research projects with expertise in molecular and cellular biology techniques, protocol based laboratory procedures, report generation, data extraction and management.

Laura Motta

Laura Motta is a Grant Advisor for the Research Department of Università Cattolica del Sacro Cuore – Rome Campus/Fondazione Policlinico Gemelli, supporting the various activities including, proposal preparation, project management, reporting and auditing, and coordination of several research projects of the Faculty of Medicine and Surgery. She is involved in various European projects and programmes and currently working for the European Commission as an auditor for the European Social Fund. She is also a project adviser at the European Research Council Executive Agency.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

March 14, 10:00-11:30 aM CET



Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.